Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

September 30, Top 20 Shareholders

210930_Top_Holders_Report

Categories: News and Announcements 2021, Top 20 ShareholdersBy Richard Mollard October 1, 2021

Related posts

October 1, Entitlement Options Issue Prospectus
October 1, 2021

October 1, Pro-Rata Non-Renounceable Entitlement Options Offer
October 1, 2021

October 1, Top 100 Shareholders
October 1, 2021

Sept 10, PharmAust Broker Briefing Presentation
September 9, 2021

August 31, Top 20 Shareholders
September 1, 2021

August 31, Epichem Pays Off EFA Loan
August 31, 2021

Recent Articles

October 1, Entitlement Options Issue Prospectus
October 1, 2021
October 1, Pro-Rata Non-Renounceable Entitlement Options Offer
October 1, 2021
October 1, Top 100 Shareholders
October 1, 2021
September 30, Top 20 Shareholders
October 1, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @PharmAust·

PharmAust doubles life expectancy of pet dogs with cancer, a major step towards commercialisation

https://stockhead.com.au/health/pharmaust-doubles-life-expectancy-of-pet-dogs-with-cancer-a-major-step-towards-commercialisation/

Reply on Twitter 1452404704596557826 Retweet on Twitter 14524047045965578261 Like on Twitter 14524047045965578266 Twitter 1452404704596557826

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions